(NewsNation– A large clinical trial comparing four common drugs used to treat type 2 diabetes found that two of the drugs were “slightly better” than the others. The National Institutes of Health (NIH) reported on Wednesday.
Funding was provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) And it started in 2013 Approaches to lowering glycemia in diabetes: a comparative effectiveness study (GRADE).Researchers found that glargine and liraglutide were better than glimepiride and sitagliptin in helping people maintain blood glucose levels.
The study, which looked at 5,047 people with type 2 diabetes at 36 study centers in the United States, is important: Of the 37 million Americans, 90 to 95 percent have type 2 diabetes.
“Knowing that we’re fighting an obesity epidemic and that the trends of type 2 diabetes are increasing, even in pediatric patients, this gives health care providers more tools to achieve (blood glucose) control,” said Dr. Ilan Shapiro, chief health reporter and chief of medical affairs at AltaMed Health Services He spoke to the NIH in Los Angeles.
Unlike type 1, patients with type 2 diabetes require more than one medication Blood sugar control With time, the level increases and the chances of developing problems like nerve, kidney and so on are high. Eye diseases.
While there is a consistent school of thought on how to treat diabetes in its early stages – Metformin Combined with diet and exercise, there’s no one-size-fits-all approach to how to reverse blood glucose levels.
“This study was designed to provide healthcare providers with valuable information on how to guide the long-term management of type 2 diabetes,” said Dr. Henry Burch, GRADE’s NIDDK project scientist, in a statement to the NIH. “This is an important step in the correct treatment of diabetes, because these results are now for each patient in the decision-making process, in terms of the level of glucose control, how well the drugs are tolerated and another part of the person. Health disorders.”
However, the study showed that none of the drugs dramatically outperformed the others, as nearly three-quarters of the participants failed to maintain their blood glucose targets during the study period.
GRADE study coordinator Dr. David M. NIH. We have much work to do, such as evaluating other interventions and treatment combinations that can help people with type 2 diabetes achieve long-term glucose control.